Biological Psychiatry, volume 74, issue 10, pages 720-726

Psychobiotics: A Novel Class of Psychotropic

Publication typeJournal Article
Publication date2013-11-01
scimago Q1
wos Q1
SJR4.684
CiteScore18.2
Impact factor9.0
ISSN00063223, 18732402
Biological Psychiatry
Abstract
Here, we define a psychobiotic as a live organism that, when ingested in adequate amounts, produces a health benefit in patients suffering from psychiatric illness. As a class of probiotic, these bacteria are capable of producing and delivering neuroactive substances such as gamma-aminobutyric acid and serotonin, which act on the brain-gut axis. Preclinical evaluation in rodents suggests that certain psychobiotics possess antidepressant or anxiolytic activity. Effects may be mediated via the vagus nerve, spinal cord, or neuroendocrine systems. So far, psychobiotics have been most extensively studied in a liaison psychiatric setting in patients with irritable bowel syndrome, where positive benefits have been reported for a number of organisms including Bifidobacterium infantis. Evidence is emerging of benefits in alleviating symptoms of depression and in chronic fatigue syndrome. Such benefits may be related to the anti-inflammatory actions of certain psychobiotics and a capacity to reduce hypothalamic-pituitary-adrenal axis activity. Results from large scale placebo-controlled studies are awaited.
Found 
Found 

Top-30

Journals

10
20
30
40
50
60
Nutrients
55 publications, 5.51%
International Journal of Molecular Sciences
23 publications, 2.3%
Scientific Reports
19 publications, 1.9%
Brain, Behavior, and Immunity
19 publications, 1.9%
Frontiers in Microbiology
17 publications, 1.7%
Food and Function
15 publications, 1.5%
Probiotics and Antimicrobial Proteins
14 publications, 1.4%
Microorganisms
12 publications, 1.2%
Frontiers in Psychiatry
11 publications, 1.1%
Frontiers in Neuroscience
10 publications, 1%
Progress in Neuro-Psychopharmacology and Biological Psychiatry
9 publications, 0.9%
Frontiers in Cellular and Infection Microbiology
8 publications, 0.8%
Frontiers in Immunology
8 publications, 0.8%
Neuroscience and Biobehavioral Reviews
8 publications, 0.8%
Advances in Experimental Medicine and Biology
8 publications, 0.8%
Holistic Nursing Practice
7 publications, 0.7%
Cells
7 publications, 0.7%
Frontiers in Nutrition
7 publications, 0.7%
Translational Psychiatry
7 publications, 0.7%
Journal of Functional Foods
7 publications, 0.7%
Journal of Agricultural and Food Chemistry
6 publications, 0.6%
Food Research International
6 publications, 0.6%
Behavioural Brain Research
6 publications, 0.6%
Critical Reviews in Food Science and Nutrition
6 publications, 0.6%
Nutrition Reviews
6 publications, 0.6%
Molecular Psychiatry
5 publications, 0.5%
PLoS ONE
5 publications, 0.5%
Psychopharmacology
5 publications, 0.5%
Neuropharmacology
5 publications, 0.5%
10
20
30
40
50
60

Publishers

50
100
150
200
250
Elsevier
247 publications, 24.72%
Springer Nature
167 publications, 16.72%
MDPI
145 publications, 14.51%
Frontiers Media S.A.
80 publications, 8.01%
Wiley
61 publications, 6.11%
Taylor & Francis
30 publications, 3%
Ovid Technologies (Wolters Kluwer Health)
25 publications, 2.5%
Oxford University Press
18 publications, 1.8%
Cambridge University Press
15 publications, 1.5%
Royal Society of Chemistry (RSC)
15 publications, 1.5%
SAGE
13 publications, 1.3%
Cold Spring Harbor Laboratory
10 publications, 1%
American Chemical Society (ACS)
9 publications, 0.9%
S. Karger AG
7 publications, 0.7%
Baishideng Publishing Group
6 publications, 0.6%
Bentham Science Publishers Ltd.
6 publications, 0.6%
Hindawi Limited
6 publications, 0.6%
Public Library of Science (PLoS)
5 publications, 0.5%
Mary Ann Liebert
5 publications, 0.5%
Wageningen Academic Publishers
5 publications, 0.5%
Pleiades Publishing
4 publications, 0.4%
Walter de Gruyter
4 publications, 0.4%
IntechOpen
4 publications, 0.4%
IMR Press
3 publications, 0.3%
Korean College of Neuropsychopharmacology
3 publications, 0.3%
American Society for Microbiology
3 publications, 0.3%
Hogrefe Publishing Group
2 publications, 0.2%
American Society for Clinical Investigation
2 publications, 0.2%
American Society for Pharmacology and Experimental Therapeutics
2 publications, 0.2%
50
100
150
200
250
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
999
Share
Cite this
GOST |
Cite this
GOST Copy
Dinan T. G., Stanton C., Cryan J. F. Psychobiotics: A Novel Class of Psychotropic // Biological Psychiatry. 2013. Vol. 74. No. 10. pp. 720-726.
GOST all authors (up to 50) Copy
Dinan T. G., Stanton C., Cryan J. F. Psychobiotics: A Novel Class of Psychotropic // Biological Psychiatry. 2013. Vol. 74. No. 10. pp. 720-726.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1016/J.BIOPSYCH.2013.05.001
UR - https://doi.org/10.1016/J.BIOPSYCH.2013.05.001
TI - Psychobiotics: A Novel Class of Psychotropic
T2 - Biological Psychiatry
AU - Dinan, Timothy G
AU - Stanton, Constance
AU - Cryan, John F.
PY - 2013
DA - 2013/11/01
PB - Elsevier
SP - 720-726
IS - 10
VL - 74
PMID - 23759244
SN - 0006-3223
SN - 1873-2402
ER -
BibTex |
Cite this
BibTex (up to 50 authors) Copy
@article{2013_Dinan,
author = {Timothy G Dinan and Constance Stanton and John F. Cryan},
title = {Psychobiotics: A Novel Class of Psychotropic},
journal = {Biological Psychiatry},
year = {2013},
volume = {74},
publisher = {Elsevier},
month = {nov},
url = {https://doi.org/10.1016/J.BIOPSYCH.2013.05.001},
number = {10},
pages = {720--726},
doi = {10.1016/J.BIOPSYCH.2013.05.001}
}
MLA
Cite this
MLA Copy
Dinan, Timothy G., et al. “Psychobiotics: A Novel Class of Psychotropic.” Biological Psychiatry, vol. 74, no. 10, Nov. 2013, pp. 720-726. https://doi.org/10.1016/J.BIOPSYCH.2013.05.001.
Found error?